Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Avoiding adverse drug reactions by pharmacogenetic testing: a systematic review of the economic evidence in the case of TPMT and AZA-induced side effects.

Compagni A, Bartoli S, Buehrlen B, Fattore G, Ibarreta D, de Mesa EG.

Int J Technol Assess Health Care. 2008 Summer;24(3):294-302. doi: 10.1017/S0266462308080392. Review.

PMID:
18601797
2.

Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease.

Priest VL, Begg EJ, Gardiner SJ, Frampton CM, Gearry RB, Barclay ML, Clark DW, Hansen P.

Pharmacoeconomics. 2006;24(8):767-81.

PMID:
16898847
4.

Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription.

Fargher EA, Tricker K, Newman W, Elliott R, Roberts SA, Shaffer JL, Bruce I, Payne K.

J Clin Pharm Ther. 2007 Apr;32(2):187-95.

PMID:
17381669
5.

A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine.

Dubinsky MC, Reyes E, Ofman J, Chiou CF, Wade S, Sandborn WJ.

Am J Gastroenterol. 2005 Oct;100(10):2239-47.

PMID:
16181376
6.

Prospects and limits of pharmacogenetics: the thiopurine methyl transferase (TPMT) experience.

van Aken J, Schmedders M, Feuerstein G, Kollek R.

Am J Pharmacogenomics. 2003;3(3):149-55. Review.

PMID:
12814323
7.

Pharmacogenetic association with adverse drug reactions to azathioprine immunosuppressive therapy following liver transplantation.

Breen DP, Marinaki AM, Arenas M, Hayes PC.

Liver Transpl. 2005 Jul;11(7):826-33. Erratum in: Liver Transpl. 2005 Sep;11(9):1150.

8.

Relevance of thiopurine methyltransferase status in rheumatology patients receiving azathioprine.

Clunie GP, Lennard L.

Rheumatology (Oxford). 2004 Jan;43(1):13-8. Epub 2003 Oct 17. Review.

PMID:
14566029
9.

Association of inosine triphosphatase 94C>A and thiopurine S-methyltransferase deficiency with adverse events and study drop-outs under azathioprine therapy in a prospective Crohn disease study.

von Ahsen N, Armstrong VW, Behrens C, von Tirpitz C, Stallmach A, Herfarth H, Stein J, Bias P, Adler G, Shipkova M, Oellerich M, Kruis W, Reinshagen M, Schütz E.

Clin Chem. 2005 Dec;51(12):2282-8. Epub 2005 Oct 7. Erratum in: Clin Chem. 2006 Aug;52(8):1628. Schütz, Ekkehard [added].

10.

Thiopurine S- methyltransferase [corrected] testing in idiopathic pulmonary fibrosis: a pharmacogenetic cost-effectiveness analysis.

Hagaman JT, Kinder BW, Eckman MH.

Lung. 2010 Apr;188(2):125-32. doi: 10.1007/s00408-009-9217-8. Erratum in: Lung. 2011 Jun;189(3):259.

PMID:
20066544
11.

Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease.

Ansari A, Arenas M, Greenfield SM, Morris D, Lindsay J, Gilshenan K, Smith M, Lewis C, Marinaki A, Duley J, Sanderson J.

Aliment Pharmacol Ther. 2008 Oct 15;28(8):973-83. doi: 10.1111/j.1365-2036.2008.03788.x.

12.

The cost-effectiveness of a pharmacogenetic test: a trial-based evaluation of TPMT genotyping for azathioprine.

Thompson AJ, Newman WG, Elliott RA, Roberts SA, Tricker K, Payne K.

Value Health. 2014 Jan-Feb;17(1):22-33. doi: 10.1016/j.jval.2013.10.007.

13.

TPMT testing before azathioprine therapy?

[No authors listed]

Drug Ther Bull. 2009 Jan;47(1):9-12. doi: 10.1136/dtb.2008.12.0033. Review.

PMID:
19129430
14.

Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe.

van den Akker-van Marle ME, Gurwitz D, Detmar SB, Enzing CM, Hopkins MM, Gutierrez de Mesa E, Ibarreta D.

Pharmacogenomics. 2006 Jul;7(5):783-92.

PMID:
16886902
15.

Pharmacoeconomics of adverse drug reactions.

Lundkvist J, Jönsson B.

Fundam Clin Pharmacol. 2004 Jun;18(3):275-80. Review.

PMID:
15147278
16.

Economic burden of haematological adverse effects in cancer patients: a systematic review.

Liou SY, Stephens JM, Carpiuc KT, Feng W, Botteman MF, Hay JW.

Clin Drug Investig. 2007;27(6):381-96. Review.

PMID:
17506589
17.

TPMT but not ITPA gene polymorphism influences the risk of azathioprine intolerance in renal transplant recipients.

Kurzawski M, Dziewanowski K, Lener A, Drozdzik M.

Eur J Clin Pharmacol. 2009 May;65(5):533-40. doi: 10.1007/s00228-009-0630-y. Epub 2009 Feb 20.

PMID:
19229528
18.

A pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: the TARGET study.

Newman WG, Payne K, Tricker K, Roberts SA, Fargher E, Pushpakom S, Alder JE, Sidgwick GP, Payne D, Elliott RA, Heise M, Elles R, Ramsden SC, Andrews J, Houston JB, Qasim F, Shaffer J, Griffiths CE, Ray DW, Bruce I, Ollier WE; TARGET study recruitment team..

Pharmacogenomics. 2011 Jun;12(6):815-26. doi: 10.2217/pgs.11.32. Epub 2011 May 3.

PMID:
21692613
19.

Outcome of patients on azathioprine: a need for a better pre-treatment assessment and dosing guideline.

Jabin D, Kumar S, Gow PJ.

N Z Med J. 2010 Oct 15;123(1324):67-73.

PMID:
20953224
20.

Supplemental Content

Support Center